166. 弾性線維性仮性黄色腫 Pseudoxanthoma elasticum Clinical trials / Disease details

臨床試験数 : 16 / 薬物数 : 27 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 28

diseases per page:

Showing 1 to 10 of 16 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04868578 (ClinicalTrials.gov)	December 13, 2022	30/3/2021	PPI Supplementation to Fight ECtopIc Calcification in PXE	Efficacy of PyROphosPHate Supplementation to Fight ECtopIc Calcification in PseudoXanthoma Elasticum ...	Pseudoxanthoma Elasticum	Dietary Supplement: study treatment PPI;Dietary Supplement: Placebo comparator	Centre Hospitalier Universitaire de Nice	NULL	Recruiting	18 Years	65 Years	All	99	N/A	France
2	NCT05569252 (ClinicalTrials.gov)	October 20, 2022	4/10/2022	A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum	A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals Wi ...	Pseudoxanthoma Elasticum	Drug: DS-1211b;Other: Placebo	Daiichi Sankyo, Inc.	PXE International	Recruiting	18 Years	75 Years	All	64	Phase 2	United States;Netherlands
3	NCT05030831 (ClinicalTrials.gov)	April 11, 2022	26/8/2021	Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing ...	A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmac ...	ATP-Binding Cassette Subfamily C Member 6 Deficiency;Pseudoxanthoma Elasticum;Generalized Arterial C ...	Drug: INZ-701	Inozyme Pharma	IQVIA Biotech	Recruiting	18 Years	69 Years	All	9	Phase 1/Phase 2	United States;United Kingdom
4	EUCTR2020-004000-33-FR (EUCTR)	10/06/2021	28/04/2021	A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of INZ-701 in Adults with ABCC6 ...	A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmac ...	Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum(PXE) MedDRA vers ...	Product Name: INZ-701 Product Code: INZ-701 INN or Proposed INN: RECOMBINANT HUMAN ECTONUCLEOTIDE PYRO ...	Inozyme Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	9	Phase 1;Phase 2	France
5	NCT04441671 (ClinicalTrials.gov)	December 8, 2020	20/1/2020	Oral Pyrophosphate Absorption in PXE Disease	Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)	Pseudoxanthoma Elasticum	Drug: Disodium Pyrophosphate	Tampere University Hospital	UMC Utrecht;Hungarian Academy of Sciences	Withdrawn	18 Years	80 Years	All	0	Phase 2	NULL
6	NCT04660461 (ClinicalTrials.gov)	February 4, 2020	3/12/2020	Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg ...	Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg ...	Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)	Drug: Lansoprazole 30mg;Drug: Placebo	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	NULL	Recruiting	18 Years	N/A	All	20	Phase 4	Spain
7	EUCTR2019-002109-24-FI (EUCTR)	01/08/2019	01/07/2019	Oral Pyrophosphate Absorption in PXE Disease	Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum- Oral Pyrophosphate Abs ...	Pseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Disea ...	Product Name: Disodiumpyrophosphate	Tampere University Hospital	NULL	Not Recruiting			Female: yes Male: yes	10	Phase 2	Finland
8	EUCTR2016-004021-16-ES (EUCTR)	31/10/2018	10/03/2017	Response to oral lansoprazole in patients with Pseudoxanthoma Elasticum	Response to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg ...	Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) MedDRA version: 19.1;Level: PT;Classification ...	Trade Name: Lansoprazole INN or Proposed INN: Lansolprazole Other descriptive name: LANSOPRAZOLE	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Spain
9	EUCTR2018-001492-20-FI (EUCTR)	20/06/2018	11/06/2018	Pyrophosphate therapy in PXE disease	Pseudoxanthoma elasticum – supplementation therapy of pyrophosphate deficiency	Pseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Disea ...	Trade Name: SODIUM ACID PYROPHOSPHATE Product Name: SODIUM ACID PYROPHOSPHATE SAPP ROR 28 FOOD GRADE Pr ...	Tampere university hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2;Phase 3	Finland
10	NCT02537054 (ClinicalTrials.gov)	September 2015	21/8/2015	Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)	Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular ...	Pseudoxanthoma Elasticum	Drug: Aflibercept	University Hospital, Bonn	NULL	Completed	18 Years	65 Years	All	15	Phase 2	Germany

First Previous1 2Next Last